Skip to main content
CNTX
NASDAQ Life Sciences

Wiseek Filing Insight

Analysis by Wiseek.ai
Sentiment info
Neutral
Importance info
4
Price
$2.51
Mkt Cap
$230.617M
52W Low
$0.49
52W High
$3.62
Market data snapshot near publication time

check_boxKey Events

  • No key events were highlighted for this filing.

auto_awesomeAnalysis

No analysis available.

At the time of this filing, CNTX was trading at $2.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $230.6M. The 52-week trading range was $0.49 to $3.62. This filing was assessed with an importance score of 4 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed CNTX - Latest Insights

CNTX
Apr 28, 2026, 4:12 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Shareholders to Vote on 100 Million Share Increase, Enabling Over 100% Potential Dilution
Sentiment: Negative
View Wiseek Article
CNTX
Apr 17, 2026, 4:29 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Context Therapeutics Seeks Shareholder Approval to Double Authorized Common Stock
Sentiment: Negative
View Wiseek Article
CNTX
Apr 02, 2026, 7:41 AM EDT
Filing Type: 8-K
Importance Score:
8
Context Therapeutics' CTIM-76 Receives FDA Fast Track Designation for Platinum-Resistant Ovarian Cancer
Sentiment: Positive
View Wiseek Article
CNTX
Apr 02, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
CTIM-76 Receives FDA Fast Track Designation for Platinum-Resistant Ovarian Cancer
Sentiment: Positive
View Wiseek Article
CNTX
Mar 23, 2026, 4:23 PM EDT
Source: Wiseek News
Importance Score:
8
Partial Response Reported for Context's CTIM-76, Key Milestones Ahead; Cash Runway into Mid-2027
Sentiment: Positive
View Wiseek Article
CNTX
Mar 23, 2026, 4:22 PM EDT
Filing Type: 8-K
Importance Score:
8
Context Therapeutics Reports Partial Response in CTIM-76 Phase 1a Trial, Extends Cash Runway
Sentiment: Positive
View Wiseek Article
CNTX
Mar 23, 2026, 4:09 PM EDT
Filing Type: 10-K
Importance Score:
8
Context Therapeutics Reports Increased Losses, $75M ATM Program, and Over 100% Potential Dilution
Sentiment: Negative
View Wiseek Article
CNTX
Mar 13, 2026, 4:09 PM EDT
Filing Type: 8-K
Importance Score:
8
Court Approves Governance Changes, Eliminating Staggered Board and 'For Cause' Director Removal
Sentiment: Positive
View Wiseek Article
CNTX
Feb 27, 2026, 4:11 PM EST
Filing Type: 8-K
Importance Score:
8
Context Therapeutics to Adopt Annual Director Elections, Resolving Shareholder Lawsuit
Sentiment: Positive
View Wiseek Article
CNTX
Jan 08, 2026, 7:43 AM EST
Filing Type: 8-K
Importance Score:
8
Context Therapeutics Reports Positive Interim Phase 1a Data for CTIM-76 and Extends Cash Runway
Sentiment: Positive
View Wiseek Article